BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
1. BTAI's SERENITY trial for agitation treatment has locked its database. 2. Topline results are expected soon, addressing a major unmet need. 3. BXCL501 has Fast Track designation for treating agitation in bipolar disorder. 4. Trial data included over 2,600 agitation episodes with robust patient oversight. 5. No FDA-approved therapies exist for home treatment of agitation.